3.Current status of liver diseases in Korea: Hepatitis B.
Hee Bok CHAE ; Jong Hyun KIM ; Ja Kyung KIM ; Hyung Joon YIM
The Korean Journal of Hepatology 2009;15(Suppl 6):S13-S24
Hepatitis B virus (HBV) infection is the one of the most common causes of the liver diseases in Korea. Since the discovery of Australia antigen (hepatitis associated antigen, or HBsAg later), hepatitis associated antigen was tested widely. HBsAg was detected in 6.6~8.6% in 1980's. Later, it decreased to 5.7% in 1990's. Remarkably, seropositivity of the children deceased to 0.2% after the nationwide vaccination program. Although hepatitis B vaccines are highly effective, the failure rate of perinatal prophylaxis in babies born to HBsAg positive mother was reported to be 4.25%. Treatment of chronic hepatitis B was initiated after the introduction of interferon alpha. Lamivudine opened a new era of oral antiviral agent, and it has been widely used in Korea since 1999. Adefovir was proven to have a good efficacy for lamivudine-resistant chronic hepatitis B. Newer potent antiviral agents such as entecavir, clevudine, and telbivudine are available currently. Further studies are warranted for understanding factors influencing natural history, improving treatment outcomes, and overcoming vaccine non-response.
Acute Disease
;
Antiviral Agents/therapeutic use
;
Hepatitis B/diagnosis/drug therapy/*epidemiology/prevention & control
;
Hepatitis B Surface Antigens/analysis
;
Hepatitis B Vaccines/administration & dosage
;
Hepatitis B, Chronic/epidemiology
;
Humans
;
Immunization Programs
;
Korea/epidemiology
;
Seroepidemiologic Studies
4.Subgenotype and Serotype Analysis of Hepatitis B virus in Korean Chronic Hepatitis B Patients Under Treatment.
Choong Hwan CHA ; Yong Hak SOHN ; Sun Young KO ; Heung Bum OH
The Korean Journal of Laboratory Medicine 2009;29(1):53-58
BACKGROUND: Hepatitis B virus (HBV) detected in Korean patients almost belongs to genotype C, which is subdivided into subgenotype C1 (or Cs) and C2 (or Ce). It was recently reported that the risk of hepatocellular carcinoma is different between subgenotype C1 and C2. Thus, we studied the distribution of subgenotypes of HBV in Korean chronic hepatitis B (CHB) patients. METHODS: Specimens of 421 patients, who were diagnosed as CHB and underwent antiviral treatment, were used. After sequence analysis for HBV S gene, subgenotype was identified through phylogenetic analysis. Utilizing the same sequence data, the distribution of serotypes was also investigated. RESULTS: Among 421 patient specimens, genotype C was found in 419 (99.5%) and genotype B in 2 (0.5%). Among the genotype C strains, 417 strains were C2 subgenotype and 2 strains were mixed subgenotypes. However, C2 was evidently found even in the mixed sequences. Serotypes of 419 HBV with genotype C were classified as follows: adr, 385 (91.9%), adw, 22 (5.3%), ayr, 2 (0.4%) and mixed serotype, 10 (2.3%). Serotype of both HBV with genotype B was adw. CONCLUSIONS: It was found that HBV detected in Korean CHB patients under treatment almost all belong to the C2 (Ce) genotype.
Antiviral Agents/therapeutic use
;
Blood Specimen Collection
;
Genotype
;
Hepatitis B virus/*classification/genetics
;
Hepatitis B, Chronic/diagnosis/drug therapy/*virology
;
Humans
;
Korea
;
Phylogeny
;
Sequence Analysis, DNA
;
Serotyping
5.Efficacy of Lamivudine Re-treatment and Relapse Patterns after Initial Lamivudine Treatment for Chronic Hepatitis B Infection.
Jong Ho PARK ; Neung Hwa PARK ; Jung Woo SHIN ; Sung Jo BANG ; Dae Hyun KIM ; Kwang Ro JOO ; Do Ha KIM
The Korean Journal of Hepatology 2003;9(3):188-197
BACKGROUND/AIMS: The post-treatment relapse patterns and efficacy of lamivudine re-treatment for relapsed patients have not been clarified. The aims of this study were to evaluate the relapse patterns after discontinuing therapy and the effects of lamivudine re-treatment for relapsed patients after HBeAg seroconversion. METHODS: Therapy was discontinued after HBeAg seroconversion in 121 patients. Sixty-six patients were relapsed and included in this study. The duration of lamivudine re-treatment therapy was from 6-35 (mean: 16) months. Post-retreatment monitoring continued for 1-40 (mean: 8.9) months. RESULTS: Among the relapsed 66 patients, 50 (75.8%) had HBeAg reappearance while 16 (24.2%) remained HBeAg negative and anti-HBe positive. The cumulative relapse rates at 3, 6, 12 and 24 months were 27%, 47%, 60% and 66%, respectively. Forty-two relapsers received lamivudine re-treatment. Among them, 33 were HBeAg positive and 9 were HBeAg negative and anti-HBe positive, Response was achieved in 31 of the 42 patients (73.8%). The cumulative response rates at 6, 9 and 12 months were 62%, 69% and 72%, respectively. Six patients (14.3%) developed viral breakthrough. All patients were HBeAg positive chronic hepatitis B. The duration of lamivudine re-treatment was the only predictable factor for response of lamivudine re-treatment. Therapy was discontinued after response in 21 patients. Eleven patients were relapsed, including 6 who were HBeAg positive and 5 who were HBeAg negative. Predictive factors for post-retreatment relapse were age and the duration of additional lamivudine therapy after response. CONCLUSIONS: The response rate of lamivudine re-treatment was significantly higher than in initial lamivudine treatments. The breakthrough and relapse rates, however, were similar in both initial and retreated lamivudine therapy.
Adult
;
Antiviral Agents/*therapeutic use
;
Female
;
Hepatitis B e Antigens/blood
;
Hepatitis B, Chronic/diagnosis/*drug therapy/virology
;
Humans
;
Lamivudine/*therapeutic use
;
Male
;
Recurrence
;
Retreatment
6.Occult Hepatitis B Virus Infection in Chronic Hepatitis C.
The Korean Journal of Gastroenterology 2013;62(3):154-159
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.
Carcinoma, Hepatocellular/complications
;
DNA, Viral/analysis
;
Hepacivirus/genetics
;
Hepatitis B/*complications/*diagnosis/drug therapy
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/*complications/*diagnosis/drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Liver/virology
;
Liver Neoplasms/complications
7.Revision and update on clinical practice guideline for liver cirrhosis.
Ki Tae SUK ; Soon Koo BAIK ; Jung Hwan YOON ; Jae Youn CHEONG ; Yong Han PAIK ; Chang Hyeong LEE ; Young Seok KIM ; Jin Woo LEE ; Dong Joon KIM ; Sung Won CHO ; Seong Gyu HWANG ; Joo Hyun SOHN ; Moon Young KIM ; Young Bae KIM ; Jae Geun KIM ; Yong Kyun CHO ; Moon Seok CHOI ; Hyung Joon KIM ; Hyun Woong LEE ; Seung Up KIM ; Ja Kyung KIM ; Jin Young CHOI ; Dae Won JUN ; Won Young TAK ; Byung Seok LEE ; Byoung Kuk JANG ; Woo Jin CHUNG ; Hong Soo KIM ; Jae Young JANG ; Soung Won JEONG ; Sang Gyune KIM ; Oh Sang KWON ; Young Kul JUNG ; Won Hyeok CHOE ; June Sung LEE ; In Hee KIM ; Jae Jun SHIM ; Gab Jin CHEON ; Si Hyun BAE ; Yeon Seok SEO ; Dae Hee CHOI ; Se Jin JANG
The Korean Journal of Hepatology 2012;18(1):1-21
No abstract available.
Antiviral Agents/therapeutic use
;
Ascites/diagnosis/prevention & control/therapy
;
Cholagogues and Choleretics/therapeutic use
;
Fatty Liver/diagnosis/diet therapy
;
Fatty Liver, Alcoholic/diagnosis/drug therapy
;
Hemorrhage/prevention & control/therapy
;
Hepatic Encephalopathy/diagnosis/prevention & control/therapy
;
Hepatitis B, Chronic/diagnosis/drug therapy
;
Hepatitis C, Chronic/diagnosis/drug therapy
;
Humans
;
Liver Cirrhosis/*diagnosis/drug therapy/pathology/*therapy
;
Liver Cirrhosis, Biliary/drug therapy
;
Vasodilator Agents/therapeutic use
8.Expert consensus on MRI diagnosis of liver fibrosis in chronic hepatitis B (version 2023).
Chinese Journal of Hepatology 2023;31(10):1009-1017
Chronic hepatitis B is a common chronic inflammatory disease of the liver in China that frequently results in sustained damage to the liver parenchyma, followed by liver fibrosis, and ultimately progresses to unfavorable outcomes such as cirrhosis, liver failure, and liver cancer. Liver fibrosis reversal can be achieved through early and effective intervention. Therefore, timely and accurate assessment of the degree of liver fibrosis is of great clinical significance for the treatment and prognosis assessment of patients with chronic hepatitis B. MRI plays a crucial role in the early assessment and monitoring of the therapeutic efficacy of liver fibrosis in chronic hepatitis B. Currently, there is a lack of uniform consensus on MRI scanning protocols and related diagnostic thresholds for liver fibrosis in chronic hepatitis B, which is not conducive to practical clinical evaluation and application. This expert consensus is based on a full review of relevant domestic and international literature and the formulation of methodologies based on evidence-based medical guidelines and standards to develop recommendations for MRI scanning techniques and the diagnosis of liver fibrosis in chronic hepatitis B, with a view to providing a clear basis for the clinical diagnosis.
Humans
;
Hepatitis B, Chronic/drug therapy*
;
Consensus
;
Liver Cirrhosis/diagnosis*
;
Liver/diagnostic imaging*
;
Magnetic Resonance Imaging/methods*